Kenneth J Woodside

Dr. Kenneth J Woodside

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in International Immunology
Verified
Journal Article
Open access
PDF file
CFChiguang Feng
Chiguang Feng
KWKenneth J Woodside
Kenneth J Woodside
BVBarbara A. Vance
Barbara A. Vance
DEDalal El‐Khoury
Dalal El‐Khoury
MCMatilde Canelles
Matilde Canelles
PLPaul E. Love
Paul E. Love
The early activation marker, CD69, is transiently expressed on activated mature T cells and on thymocytes that are undergoing positive or negative selection in the thymus. CD69 is a member of the NK gene complex family of C‐type lectin‐like signaling receptors; however, its function is unknown. In this report, we describe the characterization of mice that constitutively express high levels of surface CD69 on immature and mature T cells throughout development. Constitutive surface expression of CD69 did not affect T cell maturation, signaling through the TCR or thymocyte selection. However, phenotypically and functionally mature thymocytes accumulated in the medulla of CD69 transgenic mice and failed to be exported from the thymus. The retention of mature thymocytes correlated with transgene dose and CD69 surface levels. These results identify a potential role for CD69 in controlling thymocyte export, and suggest that the transient expression of CD69 on thymocytes and T cells may function to regulate thymocyte and T cell trafficking.

8 December 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JDJan B. DeJarnette
Jan B. DeJarnette
CSConnie L. Sommers
Connie L. Sommers
KHKun Huang
Kun Huang
KWKenneth J Woodside
Kenneth J Woodside
RERebecca Emmons
Rebecca Emmons
PLPaul E. Love
Paul E. Love
T cell antigen receptor (TCR) and pre-TCR complexes are composed of clonotypic heterodimers in association with dimers of signal transducing invariant subunits (CD3γ, -δ, -ɛ, and ζ). The role of individual invariant subunits in T cell development has been investigated by generating gene-specific mutations in mice. Mutation of CD3γ, -δ, or ζ results in an incomplete block in development, characterized by reduced numbers of mature T cells that express low levels of TCR. In contrast, mature T cells are absent from CD3ɛ −/− mice, and thymocyte development is arrested at the early CD4 − CD8 − stage. Although these results suggest that CD3ɛ is essential for pre-TCR and TCR expression/function, their interpretation is complicated by the fact that expression of the CD3γ and CD3δ genes also is reduced in CD3ɛ −/− mice. Thus, it is unclear whether the phenotype of CD3ɛ −/− mice reflects the collective effects of CD3γ, -δ, and -ɛ deficiency. By removing the selectable marker (PGK-NEO) from the targeted CD3ɛ gene via Cre/ lox P-mediated recombination, we generated mice that lack CD3ɛ yet retain normal expression of the closely linked CD3γ and CD3δ genes. These (CD3ɛ Δ/Δ ) mice exhibited an early arrest in T cell development, similar to that of CD3ɛ −/− mice. Moreover, the developmental defect could be rescued by expression of a CD3ɛ transgene. These results identify an essential role for CD3ɛ in T cell development not shared by the CD3γ, CD3δ, or ζ-family proteins and provide further evidence that PGK-NEO can influence the expression of genes in its proximity.

15 October 2012 in Transplantation
Verified
Journal Article
Closed access
JAJoshua J. Augustine
Joshua J. Augustine
KWKenneth J Woodside
Kenneth J Woodside
APAparna Padiyar
Aparna Padiyar
ESEdmund Q. Sanchez
Edmund Q. Sanchez
DHDonald E. Hricik
Donald E. Hricik
JSJames A. Schulak
James A. Schulak
Background Patients returning to dialysis therapy after renal transplant failure have a high rate of human leukocyte antigen antibody sensitization, and sensitization has been linked to allograft nephrectomy. We hypothesized that nephrectomy for cause is a consequence of weaning immunosuppression and that weaning leads to sensitization even in the absence of nephrectomy. Methods We examined outcomes in 300 consecutive patients with kidney allograft failure and survival of more than 30 days after failure. We analyzed a subset of 119 patients with a low panel reactive antibody (PRA) before transplantation and follow-up PRA testing at 6 to 24 months after failure (late PRA). Results By late PRA testing, 56% of patients were highly sensitized (class I or II PRA ≥80%). On multivariate analysis controlling for human leukocyte antigen matching, allograft nephrectomy, and other variables, weaning of immunosuppression predicted high sensitization (odds ratio, 14.34; P=0.004). In a subset of patients, the percentage of those who were highly sensitized increased from 21% at the time of failure on immunosuppressive therapy to 68% by late PRA after weaning (P<0.001). Conversely, patients who maintained immunosuppression showed minimal sensitization after failure. Transplant nephrectomy was required in 41% of patients who weaned immunosuppression versus 0% of the 24 patients who maintained immunosuppression with calcineurin inhibitor therapy after failure (P<0.001). Conclusions Weaning immunosuppression was a triggering event leading to late rejection and allograft nephrectomy and was an independent predictor of alloantibody sensitization after kidney allograft failure.

1 July 2003 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
KWKenneth J Woodside
Kenneth J Woodside
MHMingdao Hu
Mingdao Hu
ABAnn Burke
Ann Burke
MMMaki Murakami
Maki Murakami
LPLori L Pounds
Lori L Pounds
GHGlenn C Hunter
Glenn C Hunter

11 June 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MLMichelle Lubetzky
Michelle Lubetzky
ETEkamol Tantisattamo
Ekamol Tantisattamo
MMMiklos Z. Molnar
Miklos Z. Molnar
KLKrista L Lentine
Krista L Lentine
ABArpita Basu
Arpita Basu
TATarek Alhamad
Tarek Alhamad
The return to dialysis after allograft failure is associated with increased morbidity and mortality. This transition is made more complex by the rising numbers of patients who seek repeat transplantation and therefore may have indications for remaining on low levels of immunosuppression, despite the potential increased morbidity. Management strategies vary across providers, driven by limited data on how to transition off immunosuppression as the allograft fails and a paucity of randomized controlled trials to support one approach over another. In this review we summarize the current data available for management and care of the failing allograft. Additionally, we discuss a suggested plan for immunosuppression weaning based upon availability of re-transplantation and residual allograft function. We propose a shared-care model in which there is improved coordination between transplant providers and general nephrologists so that immunosuppression management and preparation for renal replacement therapy and/or repeat transplantation can be conducted with the goal of improved outcomes and decreased morbidity in this vulnerable patient group.

27 March 2014 in Transplantation
Verified
Journal Article
Closed access
KWKenneth J Woodside
Kenneth J Woodside
ZSZachary W. Schirm
Zachary W. Schirm
KNKelly A. Noon
Kelly A. Noon
AHAnne M. Huml
Anne M. Huml
APAparna Padiyar
Aparna Padiyar
JAJoshua J. Augustine
Joshua J. Augustine
Background Patients returning to dialysis therapy after renal transplant failure have high morbidity and retransplant rates. After observing frequent hospitalizations with fever after failure, it was hypothesized that maintaining immunosuppression for the failed allograft increases the risk of infection, while weaning immunosuppression can lead to symptomatic rejection mimicking infection. Methods One hundred eighty-six patients with failed kidney transplants were analyzed for rates of hospitalization with fever within 6 months of allograft failure. Patients were stratified by the presence of full immunosuppression versus minimal (low-dose prednisone) or no immunosuppression, before hospital admission. Subsequent rates of documented infection and nephrectomy, as well as patient survival, were ascertained. Results Hospitalization with fever within 6 months of allograft failure was common, occurring in 44% of patients overall. However, among febrile hospitalized patients who had been weaned off of immunosuppression before admission, only 38% had documented infection. In contrast, 88% of patients maintained on immunosuppression had documented infection (P<0.001). In both groups, dialysis catheter–related infections were the most common infection source. Allograft nephrectomy was performed in 81% of hospitalized patients with no infection, compared to 30% of patients with documented infection (P<0.001). Mortality risk was significantly higher in patients with concurrent pancreas transplants or who were hospitalized with documented infection. Conclusions Maintenance immunosuppression after kidney allograft failure was associated with a greater incidence of infection, while weaning of immunosuppression commonly resulted in symptomatic rejection with fever mimicking infection on presentation. Management of the failed allograft should include planning to avoid both infection and sensitizing events.